Droperidol Injection
- Packing: 2 Ml Ampoule.
- Available Strength : 2.5 Mg/Ml
Description
Product Description: Droperidol Injection is a meticulously formulated pharmaceutical solution designed to address various psychiatric and perioperative conditions effectively. It contains droperidol, a potent dopamine receptor antagonist with antiemetic and sedative properties. Manufactured to the highest quality standards, this injection is trusted by healthcare professionals for its reliability and efficacy in managing nausea, vomiting, and agitation.
Indications and Usage: Droperidol Injection is indicated for the management of perioperative nausea and vomiting, agitation, and psychotic disorders. It is particularly effective in preventing and treating postoperative nausea and vomiting in surgical patients and managing agitation in psychiatric emergencies.
Dosage and Administration: The dosage of Droperidol Injection varies depending on the patient's age, weight, and clinical condition. It is typically administered via intravenous route under the supervision of a qualified healthcare professional. Dosage adjustments may be necessary based on the patient's response to therapy and individual tolerance.
Dosage Forms and Strengths: Droperidol Injection is available as a sterile solution in vials containing specific concentrations of droperidol formulated for parenteral administration. Each vial is carefully manufactured to ensure accurate dosing and optimal therapeutic outcomes.
Contraindications: This product is contraindicated in patients with a known hypersensitivity to droperidol or any of the excipients. It should not be used in patients with a history of QT prolongation, ventricular arrhythmias, or concurrent use of drugs that prolong the QT interval. Additionally, it is contraindicated in patients with Parkinson's disease or untreated angle-closure glaucoma.
Warnings and Precautions: Healthcare providers should exercise caution when prescribing Droperidol Injection to patients with a history of cardiac arrhythmias, electrolyte imbalances, or hepatic impairment. Prolonged QT interval and torsades de pointes have been reported with the use of droperidol, especially in patients with preexisting risk factors. Patients should be monitored closely for signs of QT prolongation during therapy.
Adverse Reactions/Side Effects: Common adverse reactions associated with Droperidol Injection include sedation, hypotension, dizziness, and extrapyramidal symptoms such as dystonia and akathisia. Rarely, serious adverse effects such as QT prolongation, torsades de pointes, and neuroleptic malignant syndrome may occur. Patients should be advised to report any unusual symptoms promptly.
Drug Interactions: Concomitant use of Droperidol Injection with other drugs that affect dopamine receptor function or prolong the QT interval may increase the risk of adverse effects or alter the pharmacokinetics of droperidol. Healthcare providers should review the patient's medication profile carefully to avoid potential drug interactions.
Use In Specific Populations Description: Safety and efficacy of Droperidol Injection in pediatric patients, pregnant women, and nursing mothers have not been established conclusively. Healthcare providers should assess the potential risks and benefits before prescribing this medication in these populations.
How Supplied/Storage and Handling: Droperidol Injection is supplied as a sterile solution in vials for parenteral administration. It should be stored at controlled room temperature away from light and moisture. Care should be taken to avoid freezing or excessive heat exposure. Unused portions should be discarded according to standard procedures for biohazardous waste.
